Arjo AB Class B ( (ARRJF) ) has released its Q2 earnings. Here is a breakdown of the information Arjo AB Class B presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Arjo AB Class B is a prominent player in the medical technology sector, specializing in products and solutions that improve the quality of life for patients with reduced mobility and age-related health challenges. The company operates across various global markets, providing equipment and services primarily to healthcare institutions.
In its latest earnings report for Q2 2025, Arjo AB reported net sales of SEK 2,678 million, reflecting an organic growth of 3.0% despite a slight decline from the previous year’s SEK 2,810 million. The company launched a new acute care stretcher, Sentego, which is expected to bolster its product portfolio and meet the evolving needs of healthcare providers.
Key financial metrics indicated a stable performance, with a gross margin of 43.4% and an adjusted EBITDA of SEK 475 million. The company experienced double-digit growth in North America, particularly in the US, which contributed significantly to its overall performance. However, challenges such as currency effects and increased tariffs impacted profitability, resulting in a lower profit after financial items of SEK 126 million compared to SEK 164 million in the previous year.
Looking ahead, Arjo AB remains optimistic about its growth trajectory, expecting organic sales growth within the target range of 3-5% for 2025. The company is focusing on enhancing cost efficiency and expanding its product offerings to capitalize on the growing demand in the healthcare sector. Management anticipates a strong net sales development in the latter half of the year, supported by a robust order book and ongoing investments in new product launches.